Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports

This document discusses two case reports on the use of upadacitinib, a JAK 1 inhibitor, for treating alopecia areata (AA) with comorbidities. A 65-year-old female with AA and sarcoidosis and a 17-year-old male with AA and allergies both experienced significant hair regrowth after 2 years and 18 months of treatment, respectively. The study suggests upadacitinib's potential in managing AA, especially in patients with additional autoimmune or allergic conditions, but notes the limitation of a small sample size and calls for further research to confirm these findings and assess long-term effects and safety.